Lifecore Biomedical's (LFCR) "Equal Weight" Rating Reaffirmed at Stephens

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report)'s stock had its "equal weight" rating restated by stock analysts at Stephens in a research note issued on Friday,Benzinga reports. They currently have a $6.00 price target on the stock. Stephens' price objective would suggest a potential downside of 21.26% from the stock's current price.

Separately, Craig Hallum raised their price target on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday, November 22nd.

Lifecore Biomedical Trading Up 14.4 %

LFCR stock traded up $0.96 during trading on Friday, hitting $7.62. 612,393 shares of the company traded hands, compared to its average volume of 736,447. The company has a 50-day moving average of $6.98 and a 200-day moving average of $5.77. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $8.90. The firm has a market capitalization of $280.62 million, a PE ratio of 95.25 and a beta of 0.98.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last issued its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. Analysts predict that Lifecore Biomedical will post -0.99 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LFCR. Bank of New York Mellon Corp purchased a new stake in shares of Lifecore Biomedical in the 2nd quarter worth about $327,000. Rhumbline Advisers grew its holdings in Lifecore Biomedical by 1,668.5% in the second quarter. Rhumbline Advisers now owns 26,899 shares of the company's stock worth $138,000 after purchasing an additional 25,378 shares during the period. Renaissance Technologies LLC bought a new position in shares of Lifecore Biomedical during the second quarter valued at approximately $56,000. DCF Advisers LLC lifted its holdings in shares of Lifecore Biomedical by 2.1% during the second quarter. DCF Advisers LLC now owns 290,684 shares of the company's stock valued at $1,491,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Lifecore Biomedical by 87.3% during the second quarter. Marshall Wace LLP now owns 300,120 shares of the company's stock valued at $1,540,000 after purchasing an additional 139,887 shares during the last quarter. Institutional investors own 83.36% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.